<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38328496</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Reduction in Long COVID Symptoms and Symptom Severity in Vaccinated Compared to Unvaccinated Adults.</ArticleTitle><Pagination><StartPage>ofae039</StartPage><MedlinePgn>ofae039</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofae039</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofae039</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The impact of vaccination prior to infection on postacute sequelae of coronavirus disease 2019 (COVID-19, PASC), also known as long COVID, remains unclear. Here we assess the protective effect of vaccination on long COVID in a community-based setting.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The Immunity Associated with SARS-CoV-2 (IASO) study is an ongoing prospective cohort of working adults that began in October 2020. Participants are actively followed for severe acute respiratory syndrome coronavirus 2 infection. We compared the prevalence of symptoms and symptom severity in vaccinated compared to unvaccinated cases. Our primary definition of long COVID was the presence of symptoms at 90 days postinfection; 30 days postinfection was also examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Overall, by 90 days postinfection, 13% of cases had long COVID, with 27% of unvaccinated cases and 8% of vaccinated cases reporting long COVID (relative risk [RR], 0.31 [95% confidence interval {CI}, .22-.42]). Vaccination was also associated with significantly lower average severity scores at all timepoints (eg, relative severity at 90 days postinfection: -2.70 [95% CI, -1.68 to -3.73]). In the pre-Omicron era, 28% of unvaccinated cases and 18% of vaccinated cases reported long COVID (<i>P</i> = .07), and vaccinated cases reported less severe symptoms including less difficulty breathing (<i>P</i> = .01; 90-day RR, 0.07).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Vaccinated cases had lower prevalence of long COVID and reduced symptom severity.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Hannah E</ForeName><Initials>HE</Initials><Identifier Source="ORCID">0000-0001-5761-0801</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalski-Dobson</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3105-4637</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckard</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gherasim</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0004-8484-6798</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manthei</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyers</LastName><ForeName>Alyssa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Dawson</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakker</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7084-9291</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindsey</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Zijin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warsinske</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buswinka</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoneman</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valdez</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Aubree</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9352-7877</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">community-based</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. A.G. has served on a respiratory syncytial virus vaccine scientific advisory board for Janssen Pharmaceuticals and on a COVID-19 scientific advisory board for Gilead Sciences. All other authors report no potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38328496</ArticleId><ArticleId IdType="pmc">PMC10847810</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofae039</ArticleId><ArticleId IdType="pii">ofae039</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
National Center for Health Statistics, US Census Bureau . Household Pulse Survey, 2022&#x2013;2023. Long COVID. 2023. Available at: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm. Accessed 10 February 2023.</Citation></Reference><Reference><Citation>
US Census Bureau . United States adult population grew faster than nation&#x2019;s total population from 2010 to 2020. 2020. Available at: https://www.census.gov/content/dam/Census/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020-table-1.jpg. Accessed 29 March 2023.</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med 2021; 27:626&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with Delta versus Omicron variants of SARS-CoV-2. Lancet 2022; 399:2263&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Andeweg SP, Vennema H, Veldhuijzen I, et al. . Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals. Sci Transl Med 2023; 15:eabn4338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9580257</ArticleId><ArticleId IdType="pubmed">35862508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya RP, Hanage WP. Intrinsic severity of the SARS-CoV-2 Omicron variant. N Engl J Med 2022; 386:1867&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">35443125</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong JY, Cheung JK, Lin Y, et al. . Intrinsic and effective severity of COVID-19 cases infected with the ancestral strain and Omicron BA.2 variant in Hong Kong. J Infect Dis 2023; 228:1231&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">37368235</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022; 28:1461&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. . Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022; 22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun MC, Singh AK, Pal D, et al. . Characteristics, and predictors of long COVID among diagnosed cases of COVID-19. PLoS One 2022; 17:e278825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman B, Viwattanakulvanid P, Dzulhadj A, Oo AC, Patricia K, Pongpanich S. Effect of full vaccination and post-COVID olfactory dysfunction in recovered covid-19 patient. A retrospective longitudinal study with propensity matching. medRxiv [Preprint]. Posted online 11 January 2022. doi:10.1101/2022.01.10.22269007</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.10.22269007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P, Gorelik Y, Zayyad H, et al. . Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020&#x2013;21, Israel. NPJ Vaccines 2022; 7:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411827</ArticleId><ArticleId IdType="pubmed">36028498</ArticleId></ArticleIdList></Reference><Reference><Citation>Senjam SS, Balhara YPS, Kumar P, et al. . Assessment of post COVID-19 health problems and its determinants in north India: a descriptive cross section study. medRxiv [Preprint]. Posted online 7 October 2021. doi:10.1101/2021.10.03.21264490</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.03.21264490</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon MA, Luginbuhl RD, Parker R. Reduced incidence of long-COVID symptoms related to administration of COVID-19 vaccines both before COVID-19 diagnosis and up to 12 weeks after. medRxiv [Preprint]. Posted online 18 November 2021. doi:10.1101/2021.11.17.21263608</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.17.21263608</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun 2022; 103:154&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Vetter P, Chappuis F, Kaiser L, Guessous I; CoviCare Study Team . Prevalence of post-COVID condition 12 weeks after Omicron infection compared to negative controls and association with vaccination status. Clin Infect Dis 2022; 76:1567&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">36519381</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, et al. . Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ 2023; 380:e072529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon V, Kota V, Bloomquist RF, et al. . PARIS and SPARTA: finding the Achilles&#x2019; heel of SARS-CoV-2. mSphere 2022; 7:e0017922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9241545</ArticleId><ArticleId IdType="pubmed">35586986</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022; 226:1593&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, et al. . Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of Omicron and Delta variant dominance: a prospective observational study from the ZOE COVID study. Lancet 2022; 399:1618&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadfield J, Megill C, Bell SM, et al. . Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 2018; 34:4121&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6247931</ArticleId><ArticleId IdType="pubmed">29790939</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21:133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowenstein F, ed. The long COVID survival guide: how to take care of yourself and what comes next. New York: The Experiment, LLC; 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>